Bocidelpar sulfate is a Small Molecule owned by Mitobridge, and is involved in 6 clinical trials, of which 3 were completed, and 3 are ongoing.
MA-0211 acts as peroxisome proliferator-activated receptor delta (PPARdelta) agonist. PPARdelta plays important role in the regulation of mitochondrial processes in a number of tissues. The drug candidate by activating PPAR delta decreases the susceptibility to ectopic lipid deposition, metabolic diseases and thereby alleviates the disease conditions.
The revenue for Bocidelpar sulfate is expected to reach a total of $531m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bocidelpar sulfate NPV Report.
Bocidelpar sulfate was originated by Salk Institute for Biological Studies and is currently owned by Mitobridge. Astellas Pharma is the other company associated in development or marketing of Bocidelpar sulfate.
Bocidelpar sulfate Overview
MA-0211 is under development for the treatment of Duchenne muscular dystrophy (DMD), mitochondrial myopathies and fatty acid oxidation disorders including Melas syndrome, Kearns-Sayre syndrome. It is administered through oral route. The drug candidate acts by targeting peroxisome proliferator-activated receptor delta (PPARdelta). It was also under development for Leber’s hereditary optic neuropathy (LHON).
Astellas Pharma Overview
Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY1,296,163 million for the fiscal year ended March 2022 (FY2022), an increase of 3.7% over FY2021. In FY2022, the company’s operating margin was 12.4%, compared to an operating margin of 11.7% in FY2021. In FY2022, the company recorded a net margin of 9.6%, compared to a net margin of 9.7% in FY2021. The company reported revenues of JPY380,394 million for the second quarter ended September 2022, a decrease of 0.4% over the previous quarter.
Quick View – Bocidelpar sulfate
|Highest Development Stage|